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OBJECTIVES This study was designed to assess the functional importance of endothelin (ET)B receptors in
patients with left ventricular systolic dysfunction (LVSD) by comparing the hemodynamic effects
of ET-1, a nonselective ETA and ETB agonist, with ET-3, a selective ETB receptor agonist.
BACKGROUND Knowledge of the functional importance of ETB receptors in mediating vasoconstriction in
chronic heart failure will help determine whether antagonists at both ETA and ETB receptors
are required to fully prevent vasoconstriction to endogenously produced ET-1.
METHODS We infused ET-1 (5 and 15 pmol/min) and ET-3 (5 and 15 pmol/min) into two separate
groups of eight patients with LVSD with similar baseline hemodynamic indices. Hemody-
namics were measured using a pulmonary thermodilution catheter and an arterial line.
RESULTS Endothelin-1 infusion led to systemic vasoconstriction, with a rise in mean arterial pressure
(mean 6 SEM 100 6 3 to 105 6 3 mm Hg, p , 0.02) and systemic vascular resistance
(1,727 6 142 to 2,055 6 164 dyn/s/cm25, p , 0.001) and a fall in cardiac index (2.44 6 0.21
to 2.22 6 0.20 liters/min/m2, p , 0.01). Endothelin-3 infusion also led to systemic
vasoconstriction, with a rise in mean arterial pressure (99 6 6 to 105 6 6 mm Hg, p , 0.01)
and systemic vascular resistance (1,639 6 210 to 1,918 6 245 dyn/s/cm25, p , 0.01) and a
fall in cardiac index (2.66 6 0.28 to 2.42 6 0.24 liters/min/m2, p , 0.05). Pulmonary
hemodynamic measurements did not change significantly in either group.
CONCLUSIONS Both ET-1 and ET-3 infusions led to systemic vasoconstriction; the hemodynamic changes
observed were of a similar magnitude at the same molar concentration. This suggests that
ETB receptors are functionally important in mediating vasoconstriction, at least in the
systemic circulation, in patients with LVSD. (J Am Coll Cardiol 1999;33:932–8) © 1999 by
the American College of Cardiology
The endothelins are a family of potent vasoconstrictor
peptides (1,2). Endothelin-1 (ET-1) is the predominant
isoform expressed in the human vasculature (3).
See page 939
Endothelin-3 is also detectable in human plasma, although
its physiologic role remains unclear. The endothelins act via
at least two receptor subtypes, denoted ETA and ETB (4,5).
EndothelinA receptors have selective affinity for ET-1 (Ki of
0.6 nmol/liter for ET-1 compared with 140 nmol/liter for
ET-3 [6]) and are expressed primarily on vascular smooth
muscle cells and cardiac myocytes. EndothelinB receptors,
which have similar affinity for each endothelin isoform (Ki
values of 0.12 and 0.06 nmol/liter for ET-1 and ET-3,
respectively [6]), are expressed on both endothelial cells and
vascular smooth muscle. Both receptors have been shown
to mediate vasoconstriction (7,8); the endothelial ETB
receptor also mediates vasodilation via nitric oxide and
prostaglandins (9).
In patients with moderate to severe chronic heart failure
(CHF), plasma concentrations of ET-1 are elevated (10–
12), correlate with the symptomatic and hemodynamic
severity of CHF (11,12) and independently predict progno-
sis on multivariate analysis (13). There is therefore consid-
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erable interest in the therapeutic potential of endothelin
receptor antagonists in CHF (14). Uncertainty about the
role of the ETB receptor in CHF has led to controversy as
to whether selective ETA or nonselective ETA/ETB antag-
onists would be the most appropriate therapeutic agent in
CHF. Enhanced ETB-mediated vasoconstriction has been
demonstrated in coronary arteries in a canine model of CHF
using sarafatoxin S6c, a selective ETB agonist (15). Studies
of the forearm circulation in CHF patients have also shown
enhanced ETB-mediated vasoconstriction, but attenuation
of the vasoconstrictor response to ET-1, compared to
control subjects (16). Sarafatoxin S6c was again used as the
selective ETB agonist in this study. This suggests that a
nonselective ETA/ETB receptor antagonist may be required
to completely prevent vasoconstriction to endogenously
produced ET-1 in CHF.
Endothelin-3 is an endogenous, relatively selective ETB
receptor agonist in humans and is a less potent vasocon-
strictor of normal forearm resistance vessels than ET-1, a
nonselective ETA and ETB receptor agonist (8). The
hemodynamic effects of ET-3 have yet to be described in
patients with left ventricular systolic dysfunction (LVSD).
To investigate the contribution of ETA and ETB receptors
to ET-mediated vasoconstriction in patients with LVSD,
we compared the hemodynamic effects of ET-1 and ET-3
in two separate groups of patients with LVSD, with or
without overt heart failure.
METHODS
Patient selection. Patients with chronic LVSD, defined as a
left ventricular ejection fraction of ,40%, measured by echo-
cardiography using Simpson’s biplane method or radionuclide
ventriculography, were eligible for study. Patients with unsta-
ble angina, known critical coronary stenoses at angiography,
valvular heart disease, atrial fibrillation, insulin-dependent
diabetes, uncontrolled hypertension and chronic renal impair-
ment (creatinine .200 mmol/liter) were excluded.
Study protocols. Studies were conducted with the approval
of the local ethics committee and with the written, informed
consent of each patient. Cardiac medications were withheld for
a minimum of 24 h before the study. Patients were fasted for
4 h before the study. Studies took place in the cardiac
catheterization laboratory. Heart rate was recorded electrocar-
diographically. Hemodynamics were measured by pulmonary
thermodilution catheter and femoral arterial line. Systemic
arterial, right atrial (RAP), pulmonary arterial and pulmonary
capillary wedge pressure (PCWP) measurements were made
simultaneously. Cardiac output (CO) was measured, in tripli-
cate, at each time point. Cardiac index (CI), and systemic
(SVR) and pulmonary (PVR) vascular resistance were calcu-
lated from standard formulae (17). Heparin (2,500 U) was
given as standard prophylaxis against thrombus formation.
Baseline hemodynamic measurements were obtained at a
minimum of 15 min postinstrumentation and repeated at
5-min intervals until stable. Sodium nitroprusside (SNP)
was then infused centrally at 0.56 and 1.12 mg/kg/min to
assess vasodilator reserve. After 5 min of each dose a
complete set of hemodynamic measurements was taken.
After hemodynamic values had returned to baseline (ap-
proximately 30 min), either ET-1 or ET-3 (Clinalfa,
Switzerland) were infused at 5 and 15 pmol/min. Each dose
was infused for 20 min with hemodynamic measurements
being made at 5 and 15 min. Further measurements were
taken 5 and 15 min after the infusion was complete.
Measurement of plasma endothelin concentrations. In
six patients from the ET-1 group, and in all eight patients
from the ET-3 group, blood samples were taken from the
femoral artery at baseline before SNP infusion, after rees-
tablishment of a baseline before ET infusion, at the end of
each dose of ET and at 5 and 15 min of recovery. Blood was
collected into chilled tubes containing 4% ethylenedia-
minetetraacetic acid. Samples were kept on ice and were
then centrifuged at 4°C. Separated plasma samples were
immediately stored at 220°C.
Endothelin-1 and big ET-1 were assayed directly (and
separately) using enzyme immunoassays (Biomedica). The
kits incorporate an immunoaffinity purified polyclonal cap-
ture antibody and a monoclonal detection antibody, both
highly specific for endothelin (1–21) or big endothelin
(1–38). Samples were assayed in duplicate and averaged.
Endothelin (1–28) assay characteristics include measur-
ing range: 0.1 to 15.6 fmol/ml; cross-reactivity—ET-1:
100%, ET-2: 100%, ET-3: ,5%, big endothelin (1–38):
,1%, big endothelin (22–38): ,1%.
Big endothelin (1–38) assay characteristics include mea-
suring range: 0.025 to 6.25 fmol/ml; cross-reactivity—big
endothelin (1–38): 100%, big endothelin (22–38): ,1%,
ET-1: ,1%, ET-2: ,1%, ET-3: ,1%.
Statistics. Baseline values are reported as mean 6 SD and
values relating to an intervention are reported as mean 6
SEM. The primary measures of interest were the changes in
PVR and SVR from baseline to the peak (15 pmol/min)
doses of ET-1 and ET-3. Repeated measures analysis of
variance examining the effects of duration of infusion, ET-1
versus ET-3 and dose was applied to the data. Significant
Abbreviations and Acronyms
CHF 5 chronic heart failure
CI 5 cardiac index
CO 5 cardiac output
DCM 5 dilated cardiomyopathy
ET 5 endothelin
LVSD 5 left ventricular systolic dysfunction
MPAP 5 mean pulmonary artery pressure
PCWP 5 pulmonary capillary wedge pressure
PVR 5 pulmonary vascular resistance
RAP 5 right atrial pressure
SNP 5 sodium nitroprusside
SVR 5 systemic vascular resistance
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differences were further explored using Student paired t test
(two tailed) with a Bonferroni correction for multiple
comparisons. Values were considered significantly different
if p , 0.05 after correction for multiple comparisons.
RESULTS
Patient characteristics. Eight patients with similar base-
line hemodynamic indices and baseline characteristics took
part in each study (i.e., eight patients received ET-1 and
eight patients received ET-3). Six patients had symptomatic
heart failure and two patients had asymptomatic left ven-
tricular dysfunction in each group. One patient had a history
of systemic hypertension and one patient had non–insulin-
dependent diabetes in each group. Further characteristics
are given in Table 1.
Sodium nitroprusside infusion. Table 2 demonstrates the
hemodynamic effects of SNP in these patient groups. As
reported in previous studies SNP infusion led to systemic
and pulmonary vasodilation. Mild flushing was reported by
a minority of patients.
Endothelin-1 infusion. Endothelin-1 infusion (15 pmol/min)
caused systemic vasoconstriction with a rise in mean arterial
pressure (6%) and SVR (20%), and a fall in CO (9%) (Table
3). There were nonsignificant trends toward a rise in PCWP
(and hence trends to a fall in transpulmonary gradient) and,
therefore, PVR remained unchanged despite the fall in CO.
No side effects were noted with ET-1 infusion.
Endothelin-3 infusion. Endothelin-3 infusion (15 pmol/
min) caused systemic vasoconstriction with a rise in mean
arterial pressure (7%) and SVR (18%), and a fall in CO (8%)
(Table 4). There were nonsignificant trends toward a rise in
mean pulmonary artery pressure (MPAP), PCWP and
PVR. One patient (DCM, New York Heart Association
class III) became breathless during the 15 pmol/min dose,
with a rise in PCWP (14 to 19 mm Hg) and a rise in MPAP
(24 to 29 mm Hg, i.e., transpulmonary gradient was un-
changed). A diuretic was given, and the symptoms resolved
quickly on stopping ET-3. There were no other adverse events.
Figure 1 shows changes in SVR in response to ET-1 and
ET-3 infusion.
Plasma ET-1 concentrations. Figure 2 shows the femoral
plasma ET-1 concentrations during ET-1 (six patients) and
ET-3 infusion (seven patients). Plasma concentrations of
ET-1 rose significantly during ET-1 infusion (baseline
pre-SNP to 15 pmol/min ET-1, p , 0.01), whereas plasma
ET-1 did not change with ET-3 infusion. Femoral plasma
big ET concentrations did not change significantly during
the studies: baseline pre-SNP: 0.63 6 0.10 and 0.83 6 0.14
fmol/ml, ET 15 pmol/min: 0.64 6 0.12 and 0.88 6 0.10
Table 1. Patient Characteristics
ET-1 Study ET-3 Study
Sex, n 7M/1F 7M/1F
Age, years (mean 6 SD) 62 6 10 64 6 11
Etiology 5 IHD, 3 DCM 6 IHD, 2 DCM
NYHA class
I 2 2
II 3 4
III 3 2
LVEF (mean 6 SD) 28 6 7% 26 6 7%
Drug therapy*
ACE-I 6 6
Diuretic 4 4
Digoxin 1 2
Calcium antagonist 1 1
Oral nitrate 3 2
Beta-blocker 3 3
Aspirin 4 6
*Drug therapy withheld for 24 h.
ACE-I 5 angiotensin-converting enzyme inhibitor; DCM 5 dilated cardiomy-
opathy; ET 5 endothelin; F 5 female; IHD 5 ischemic heart disease; LVEF 5 left
ventricular ejection fraction; M 5 male; NYHA 5 New York Heart Association.
Table 2. Hemodynamic Responses to Sodium Nitroprusside
SNP/ET-1 Group SNP/ET-3 Group Comparison: Baseline to
End of SNP Infusion
(ET-1 and ET-3 Groups Combined)Baseline Mean Change Baseline Mean Change
HR 76 6 17 110 6 2 67 6 15 113 6 3 p , 0.0001
MAP 100 6 9 224 6 4 101 6 18 227 6 5 p , 0.0001
RAP 5 6 2 21 6 1 6 6 2 22 6 1 p , 0.01
MPAP 20 6 4 29 6 1 20 6 5 210 6 1 p , 0.0001
PCWP 12 6 3 28 6 1 12 6 4 28 6 1 p , 0.0001
TPG 7.5 6 1.5 21.1 6 0.9 8.0 6 2.3 21.6 6 0.7 p , 0.05
CI 2.63 6 0.62 10.16 6 0.10 2.68 6 0.64 10.22 6 0.11 p , 0.05
SVR 1,617 6 287 2464 6 68 1,615 6 495 2505 6 83 p , 0.0001
PVR 126 6 24 227 6 14 132 6 44 235 6 11 p , 0.01
Baseline values: mean 6 SD; mean change given as mean 6 SEM; p values are for both endothelin ET-1 and ET-3 groups combined.
CI 5 cardiac index (liters/min/m2); HR 5 heart rate (beats/min); MAP 5 mean arterial blood pressure (mm hg); MPAP 5 mean pulmonary artery pressure (mm Hg);
PCWP 5 pulmonary capillary wedge pressure (mm Hg); PVR 5 pulmonary vascular resistance (dyn/s/cm25); RAP 5 right atrial pressure (mm Hg); SNP 5 sodium
nitroprusside; SVR 5 systemic vascular resistance (dyn/s/cm25); TPG 5 transpulmonary gradient (mm Hg).
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fmol/ml for ET-1 and ET-3, respectively. One patient in
the ET-3 group had very high baseline plasma ET-1
concentrations, which also did not change during ET-3
infusion (baseline pre-SNP infusion: 12.5 fmol/ml, ET-3
15 pmol/min: 12 fmol/ml). This outlying data set is not
included in Figure 1 to avoid misrepresentation of results.
The patient’s hemodynamic response was broadly similar to
other group members.
DISCUSSION
This study shows that equal molar concentrations of ET-1
and ET-3 cause a similar degree of systemic vasoconstric-
tion in patients with LVSD, with or without overt heart
failure. As ET-1 acts as a nonselective ETA/ETB receptor
agonist and ET-3 acts as a selective ETB receptor agonist at
the infused concentrations (8), this suggests that ETB
receptors are functionally important in mediating vasocon-
striction, at least in the systemic circulation, in patients with
LVSD. We did not see systemic vasodilation before vaso-
constriction as seen in forearm studies, though, as this
phenomenon has only been seen transiently with high dose
local infusion (60 pmol/min) (8), we would not have
expected to see this effect. We have previously reported the
lack of pulmonary vasoconstriction in response to exogenous
ET-1 in patients with LVSD (18). Similarly, in this study,
we saw no significant changes in MPAP or PVR with ET-3
infusion.
To our knowledge, the pulmonary and cardiac hemody-
namic effects of ET-3 have not previously been described in
humans in vivo. Inoue et al. first reported the effects of the
ET-1 and ET-3 in anesthetized rats and found ET-1 to be
the more potent vasoconstrictor (3). In a study of rabbits,
both ET-3 and ET-1 caused modest vasoconstriction in the
pulmonary vascular bed (ET-1 . ET-3), but both caused
systemic vasodilation (19). The authors noted that the
limited effects of ET-1 and ET-3 on the pulmonary bed
were in marked contrast to the potent vasoconstriction seen
with isolated pulmonary conductance vessels in vitro (19).
In human pulmonary resistance arteries, in vitro, ETB
receptor-mediated vasoconstriction predominates at physi-
ologically relevant concentrations (20). In the only in vivo
study of ET-3 reported in humans, ET-3 vasoconstricted
forearm resistance vessels of healthy volunteers, although to
a lesser extent than ET-1 (8). This suggests that both ETA
and ETB receptors mediate vasoconstriction in vivo, at least
in the normal forearm vascular bed. The less potent vaso-
constriction observed with ET-3 (8) may reflect a greater
effect on endothelial ETB receptors, the resultant vasodila-
Table 3. Hemodynamic Responses to Endothelin-1
Baseline
ET-1
(5 pmol/min)
ET-1
(15 pmol/min)
Comparison: Baseline to
End of ET-1
(15 pmol/min) Infusion
HR 73 6 18 72 6 6 73 6 6 NS
MAP 100 6 8 102 6 2 105 6 3 p , 0.02
RAP 6 6 1 5 6 1 5 6 1 NS
MPAP 21 6 6 21 6 2 22 6 2 NS
PCWP 13 6 6 14 6 2 15 6 2 NS
TPG 8 6 1 7 6 1 7 6 1 NS
CI 2.44 6 0.58 2.34 6 0.16 2.22 6 0.20 p , 0.01
SVR 1,727 6 403 1,849 6 105 2,055 6 164 p , 0.01
PVR 152 6 44 140 6 21 149 6 15 NS
Baseline values: mean 6 SD; ET-1 (5 and 15 pmol/min) given as mean 6 SEM. Abbreviations as in Table 2.
Table 4. Hemodynamic Responses to Endothelin-3
Baseline
ET-3
(5 pmol/min)
ET-3
(15 pmol/min)
Comparison: Baseline to
End of ET-3
(15 pmol/min) Infusion
HR 67 6 14 67 6 6 68 6 6 NS
MAP 99 6 17 101 6 6 105 6 6 p , 0.01
RAP 6 6 2 5 6 1 5 6 1 NS
MPAP 19 6 4 20 6 2 21 6 2 NS
PCWP 12 6 4 12 6 2 13 6 2 NS
TPG 7 6 2 7 6 1 8 6 1 NS
CI 2.66 6 0.79 2.49 6 0.25 2.42 6 0.24 p , 0.05
SVR 1,639 6 593 1,782 6 222 1,918 6 245 p , 0.01
PVR 124 6 34 133 6 13 132 6 14 NS
Baseline values: mean 6 SD; ET-3 (5 and 15 pmol/min) given as mean 6 SEM. Abbreviations as in Table 2.
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tion offsetting the smooth muscle ETA- and ETB-receptor–
mediated vasoconstriction.
In contrast to studies in healthy volunteers, we found that
ET-1 and ET-3 have very similar hemodynamic effects at
the same molar concentration in patients with LVSD, with
or without overt heart failure. This observation adds to the
growing evidence that endothelin receptor function is dis-
turbed in heart failure. Love et al. demonstrated enhanced
forearm vasoconstriction in CHF patients to sarafatoxin
S6c, a highly selective ETB receptor agonist in CHF, but
attenuation of the vasoconstrictor response to ET-1, com-
pared to control participants (16). There is also evidence for
impaired vasoconstriction to ET-1 in human CHF vessels
in vitro (21). Our data are consistent with enhanced
ETB-mediated vasoconstriction, possibly due to down-
regulation of endothelial ETB receptors. Alternatively, or in
addition, there may be attenuated ETA-mediated vasocon-
striction in the systemic circulation in LVSD/CHF.
It is possible, however, that the vasoconstriction observed
during ET-3 infusion is not ETB mediated. An alternative
explanation is that the ETB receptor agonist displaces ET-1
from the receptor and this causes unopposed vasoconstric-
tion at the ETA receptor. Similarly, the ETB receptor has
been demonstrated to act as a clearance receptor for endo-
Figure 1. Sequential changes in systemic vascular resistance (SVR) in response to endothelin-1 (ET-1) and endothelin-3 (ET-3) infusion.
Compared with baseline measurements, the rise in SVR was significant at a 15 pmol/min dose of ET-1 and ET-3 respectively, *p , 0.01.
Repeated measures analysis of variance failed to demonstrate differences between ET-1 and ET-3 or between 5 and 15 min of infusion
at each dose.
Figure 2. Sequential changes in mean plasma endothelin-1 (ET-1) concentration in response to endothelin-1 (ET-1) and endothelin-3
(ET-3) infusion. Compared with baseline values, the rise in plasma ET-1 concentration observed during ET-1 infusion (15 pmol/min)
was significant, *p , 0.01. SNP 5 sodium nitroprusside.
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thelin in animals (22,23), and therefore an ETB receptor
agonist could lead to increased ET-1 concentrations by
blocking ET-1 clearance. An early report has suggested
that, in dogs, plasma ET-1 concentrations rise with admin-
istration of both an ETB-selective agonist, sarafatoxin S6c,
and antagonists of the ETB receptor (24). We found that
circulating plasma concentrations of ET-1 did not change
with ET-3 infusion, in contrast to the rise seen with ET-1
infusion (Fig. 2). This makes the above hypotheses unlikely,
though it is still possible that changes in ET-1 concentra-
tions occur at a tissue, but not at a plasma level.
Endothelin-3 could also mediate vasoconstriction via a
putative ETC receptor (ET-3 selective), situated on smooth
muscle cells. However, although there is evidence from
binding and functional studies to support the existence of an
ET-3 selective receptor in the vasculature (25–27), and a
potential candidate has been identified in Xenopus laevis
melanophores (28), and more recently in chickens (29), such
a receptor has not yet been identified in humans.
Clarification of the functional importance of ETB receptors
in CHF, in mediating both vasodilation and vasoconstriction,
is necessary to determine whether nonselective ETA/ETB
receptor or selective ETA receptor antagonists are likely to be
the more effective vasodilator class in CHF. Our data suggest
that a nonselective ETA/ETB receptor antagonist may be
necessary to fully inhibit the vasoconstrictor effects of endog-
enous ET-1. Indeed, bosentan, which is such an agent, caused
pulmonary and systemic vasodilation in CHF patients (30).
However, a study in a canine model (31) and an early report
from human forearm studies (32) found that parenteral ad-
ministration of selective ETB receptor antagonists caused
vasoconstriction in CHF, suggesting that ETA-selective an-
tagonists might be more potent vasodilators than nonselective
agents in this syndrome. The reasons for this discrepancy have
yet to be elucidated.
Conclusions. Endothelin-1 and ET-3, when infused into
patients with LVSD, led to systemic vasoconstriction, with
little or no effect in the pulmonary vasculature. The hemody-
namic changes observed were of a similar magnitude at the
same molar concentration. This suggests that ETB receptors
are functionally important in mediating vasoconstriction, at
least in the systemic circulation, in patients with LVSD.
Studies of the pulmonary and systemic effects of selective
endothelin antagonists in patients with CHF are required
before concluding that nonselective ETA/ETB receptor antag-
onists have the greater potential as vasodilating agents in CHF.
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